After the FDA declined to approve Lykos Therapeutics’ MDMA-assisted therapy for post-traumatic stress disorder, companies are pivoting away from or delaying similar therapeutics targeting the psychiatric disease.
MDMA Drug Developers Reprioritize Following Lykos Rejection in PTSD Read More »
Already approved in six indications, Sanofi and Regeneron can now add chronic obstructive pulmonary disease to the list for their blockbuster injection.
Sanofi and Regeneron’s Dupixent Snags First Biologic Approval in COPD Read More »
Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in sales by the end of the decade, has left patients and healthcare providers with few options, while investors question the pharma giant’s dealmaking prowess.
Pfizer’s Oxbryta Withdrawal Leaves Sickle Cell Community Scrambling, Investors Reeling Read More »
The FDA’s Oncology Drugs Advisory Committee voted near-unanimously that the benefits of PD-1 inhibitors like Keytruda and Opdivo in PD-L1 low patients do not outweigh the risks.
FDA Adcomm Recommends Limiting Keytruda, Opdivo Use in Stomach, Esophageal Cancer Read More »
Fred Moll, founder of surgical robotics firms Intuitive Surgical and Auris Health, participated in in the financing round, along with previous Auris investors.
Mendaera raises $73M to develop handheld robotics platform Read More »
In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis versus placebo, positioning Roche’s therapeutic antibody for expansion into the indication.
Roche Looks to Push Gazyva Into Lupus Nephritis With Promising Late-Stage Data Read More »
Independent hospitals can receive efficiency and profitability boosts from acquisitions. However, buyouts don’t continue to boost operating metrics for corporate-owned hospitals, according to a new study.
Acquisitions work as a one-time efficiency boost for hospital margins: study Read More »
Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District Court of Texas, claiming that the company misled investors regarding the Phase IIb performance of its Alzheimer’s disease drug candidate.
Cassava Agrees to Pay $40M Fine to Resolve SEC Probe as Company Hit With New Lawsuit Read More »
Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, will help AbbVie as it builds a regulatory case for the D1/D5 dopamine receptor agonist.
AbbVie’s $8.7B Cerevel Buy Starts to Pay off With Phase III Parkinson’s Win Read More »
Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s rival drugs, is not fair.
Lilly Is Not ‘Feeling the Bern’ on Drug Prices Like Novo: Why the Double Standard? Read More »
